Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fortress Biotech Inc FBIO

Alternate Symbol(s):  FBIOP

Healthcare Biotechnology
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions... see more

Recent & Breaking News (NDAQ:FBIO)

Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results

GlobeNewswire July 21, 2020

Fortress Biotech Added to Russell 3000® Index

GlobeNewswire June 29, 2020

Fortress Biotech to Present at the Raymond James Human Health Innovation Conference

GlobeNewswire June 15, 2020

Mustang Bio Announces Pricing of Public Offering of Common Stock

GlobeNewswire June 11, 2020

Fortress Biotech Announces Publication of Study on Estimated Birth Prevalence of Menkes Disease in Molecular Genetics and Metabolism Reports

GlobeNewswire June 11, 2020

Mustang Bio Announces Proposed Public Offering of Common Stock

GlobeNewswire June 10, 2020

Avenue Therapeutics Announces Publications in Peer-Reviewed Journals

GlobeNewswire June 5, 2020

Mustang Bio to Host Virtual Annual Meeting of Stockholders

GlobeNewswire June 4, 2020

Fortress Biotech to Host Virtual Annual Meeting of Stockholders

GlobeNewswire June 2, 2020

Avenue Therapeutics to Host Virtual Annual Meeting of Stockholders

GlobeNewswire May 29, 2020

Fortress Biotech Announces Pricing of Series A Preferred Stock Offering

GlobeNewswire May 26, 2020

Checkpoint Therapeutics to Host Virtual Annual Meeting of Stockholders

GlobeNewswire May 22, 2020

Mustang Bio Announces Presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy

GlobeNewswire May 12, 2020

Fortress Biotech Reports Record First Quarter 2020 Financial Results and Recent Corporate Highlights

GlobeNewswire May 11, 2020

Mustang Bio Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

GlobeNewswire May 11, 2020

Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

GlobeNewswire May 11, 2020

Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers

GlobeNewswire May 8, 2020

Checkpoint Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

GlobeNewswire May 6, 2020

INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Fortress Biotech, Inc. for Potential Breach of Fiduciary Duty Claims.

GlobeNewswire April 30, 2020

Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters

GlobeNewswire April 23, 2020